Get started

Financials · NTLA

Intellia Therapeutics Inc. (NTLA) financials

For the twelve months ended Sep 30, 2026, Intellia Therapeutics Inc. reported $52.89M of revenue and -$426.14M of net income.

Revenue, TTM
$52.89M
Revenue growth, YoY
-8.1%
Net income, TTM
-$426.14M
Net margin
-805.7%
Free cash flow, TTM
-$358.08M
EPS, diluted, TTM
-$3.33
Cash
$156.10M
Total debt
$73.73M
P/S
30.06
Market cap
$1.59B
Annual revenue$67.67M
FY2016FY2025
Annual net income-$412.69M
FY2016FY2025
Annual free cash flow-$395.87M
FY2016FY2025

NTLA revenue and earnings growth

NTLA revenueQ3 2026$7.16M

Quarter YoY
-48.0%
QoQ
-6.5%
FY YoY
+16.9%
5Y CAGR
+3.1%

NTLA revenue was $7.16M in fiscal Q3 2026 (ended Sep 30, 2026), down 48.0% from a year earlier and down 6.5% from the prior quarter. For the full fiscal 2025 it was $67.67M, up 16.9% from fiscal 2024. Compound annual growth was +3.1% over 5 years. It rose in 7 of the last 9 fiscal years. Fiscal 2025 is the highest of the 10 fiscal years on file.

NTLA net incomeQ3 2026-$127.48M

NTLA net income was -$127.48M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$101.32M a year earlier. For the full fiscal 2025 it was -$412.69M, compared with -$519.02M in fiscal 2024.

NTLA EPSQ3 2026-$0.91

NTLA diluted EPS was -$0.91 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.92 a year earlier. For the full fiscal 2025 it was -$3.81, compared with -$5.25 in fiscal 2024.

NTLA free cash flowQ3 2026-$86.32M

NTLA free cash flow was -$86.32M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$76.93M a year earlier. For the full fiscal 2025 it was -$395.87M, compared with -$354.66M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$67.67M$57.88M$36.27M$52.12M$33.05M$57.99M$43.10M$30.43M$26.12M$16.48M
Cost of revenue----$0$0$0$0--
Gross profit----$33.05M$57.99M$43.10M$30.43M--
Research and development$388.86M$466.31M$435.07M$419.98M$229.81M$150.41M$108.41M$89.11M$67.65M$31.84M
Selling, general and admin$119.80M$125.83M$116.50M$90.31M$71.10M$44.17M$41.06M$32.19M$28.02M$16.80M
Operating income-$440.99M-$534.26M-$515.29M-$458.16M-$267.85M-$136.58M-$106.37M-$90.87M-$69.56M-$32.16M
Pre-tax income---------$67.54M-$31.63M
Income tax$0--------$0
Net income-$412.69M-$519.02M-$481.19M-$474.19M-$267.89M-$134.23M-$474.19M-$85.34M-$67.54M-$31.63M
EPS, basic-$3.81-$5.25-$5.42-$6.16-$3.78-$2.40-$2.11-$1.98-$1.88-$1.42
EPS, diluted-$3.81-$5.25-$5.42-$6.16-$3.78-$2.40-$2.11-$1.98-$1.88-$1.42
Diluted shares108.4M98.8M88.8M77.0M70.9M56.0M47,24743.1M36.0M22.2M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$155.46M$189.18M$226.75M$523.51M$123.41M$160.02M$57.23M$58.86M$340.68M$273.06M
Short-term investments$294.42M$412.33M$685.48M$669.12M$625.28M$437.35M$222.50M$255.20M--
Receivables$9.47M$8.52M$36.46M$3.77M$2.03M$2.13M$4.62M$7.55M$10.47M$6.45M
Current assets$527.71M$639.86M$998.33M$1.22B$769.30M$616.52M$289.48M$324.98M$354.83M$281.31M
Total assets$842.13M$1.19B$1.30B$1.52B$1.29B$676.32M$334.28M$347.31M$376.24M$298.97M
Current liabilities$103.88M$110.85M$115.21M$126.55M$125.83M$64.25M$35.63M$40.57M$31.36M$30.73M
Long-term debt$0---------
Total debt$0---------
Total liabilities$170.73M$319.06M$250.81M$284.53M------
Shareholders' equity$671.39M$871.96M$1.05B$1.24B$1.04B$527.07M$269.88M$277.92M$300.60M$209.84M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$394.74M-$348.88M-$394.09M-$333.29M-$225.03M-$49.91M-$103.24M-$61.26M-$65.28M$36.11M
Capital expenditures$1.13M$5.78M$13.98M$13.56M$12.76M$3.58M$6.79M$6.36M$10.09M$6.17M
Free cash flow-$395.87M-$354.66M-$408.07M-$346.85M-$237.79M-$53.50M-$110.03M-$67.61M-$75.37M$29.94M
Investing cash flow$228.03M$125.57M-$31.35M$160.31M-$550.78M-$214.49M$25.18M-$260.78M-$10.09M-$6.17M
Financing cash flow$131.49M$185.75M$130.32M$582.96M$736.69M$371.78M$76.43M$40.22M$142.98M$167.30M
Stock-based compensation$80.22M$154.27M$134.05M$91.40M$47.01M$19.90M$15.09M$17.05M$15.32M$6.71M
Depreciation and amortization$9.77M$10.29M$8.98M$7.57M$6.89M$6.31M$5.59M$4.46M$2.99M$1.10M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY16.9%59.6%-30.4%57.7%-43.0%34.5%41.6%16.5%58.5%-
Gross margin----100.0%100.0%100.0%100.0%--
Operating margin-651.7%-923.1%-1420.5%-879.0%-810.4%-235.5%-246.8%-298.6%-266.3%-195.2%
Net margin-609.9%-896.8%-1326.5%-909.8%-810.5%-231.5%-1100.1%-280.4%-258.6%-192.0%
Free cash flow margin-585.0%-612.8%-1124.9%-665.5%-719.4%-92.2%-255.3%-222.2%-288.6%181.7%
Return on equity-61.5%-59.5%-45.8%-38.4%-25.8%-25.5%-175.7%-30.7%-22.5%-15.1%
Return on assets-49.0%-43.6%-37.0%-31.2%-20.7%-19.8%-141.9%-24.6%-18.0%-10.6%
Current ratio5.085.778.679.616.119.598.128.0111.329.15
Debt to equity0.00---------

Source: XBRL data Intellia Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

NTLA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
NTLA$52.89M-8.1%-$426.14M-805.7%$1.59B
IDXX$4.66B+11.9%$1.18B25.4%$53.26B
ORKA---$132.89M-$6.81B
LNTH$1.56B+2.4%$269.90M17.3%$6.57B
NEOG$883.99M-0.3%-$56.10M-6.3%$2.57B
CLDX$158.0K-93.9%-$309.06M-195608.9%$2.35B
QDEL$2.59B-4.5%-$369.20M-14.2%$733.5M
ACHV---$114.04M-$691.0M
MYGN$803.60M-2.6%-$129.10M-16.1%$565.8M

NTLA FAQ

8 questions
  • What is NTLA revenue?
    Intellia Therapeutics Inc. (NTLA) reported $52.89M of revenue for the twelve months ended Sep 30, 2026. That is down 8.1% from the year before. Revenue for fiscal 2025 was $67.67M.
  • Is NTLA profitable?
    No. Intellia Therapeutics Inc. reported a net loss of $426.14M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does NTLA have?
    Intellia Therapeutics Inc. reported $156.10M in cash and cash equivalents and $73.73M of debt on its most recent balance sheet in SEC filings.
  • How fast is NTLA revenue growing?
    Intellia Therapeutics Inc.'s revenue changed +16.9% in fiscal 2025, to $67.67M. Its compound annual growth rate was +3.1% over 5 years.
  • What is NTLA free cash flow?
    Intellia Therapeutics Inc. generated -$358.08M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$355.17M less capital expenditures.
  • What is NTLA earnings per share?
    Diluted earnings per share were -$3.33 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did NTLA last report financial results?
    The latest statements here come from Intellia Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this NTLA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Intellia Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.